quinuclidines has been researched along with fluticasone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 10 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Antohe, I; Antoniu, SA; Gavrilovici, C | 1 |
| Birk, R; Brealey, N; Lipson, DA; Locantore, N; Lomas, DA; Pascoe, S; Tabberer, M; Zhu, CQ | 1 |
| Steurer, J | 1 |
| Baker, T; Briggs, A; Driessen, M; Ismaila, AS; Naya, I; Risebrough, N; Shah, D | 1 |
| Bogart, MR; Coutinho, AD; Hopson, SD; Shih, HC; Stanford, RH | 1 |
| Bailes, Z; Bernstein, D; Dahl, R; Fowler, A; Kerwin, E; Lee, L; Nathan, R; Pascoe, S; Robbins, K; von Maltzahn, R | 1 |
| Abbott, T; Balmaceda, C; Espinoza, MA; Peters, A | 1 |
| Baio, G; Criner, GJ; Gabrio, A; Gunsoy, NB; Halpin, DMG; Han, MK; Ismaila, AS; Lipson, DA; Martin, A; Martin, N; Martinez, FJ; Paly, VF; Risebrough, N; Singh, D; Wise, RA | 1 |
| Bardsley, S; Berkman, N; Criner, GJ; Halpin, DMG; Han, MK; Hanania, NA; Hill, D; Lange, P; Lipson, DA; Martinez, FJ; Midwinter, D; Siler, TM; Singh, D; van Zyl-Smit, RN; Wise, RA | 1 |
| Bengtson, LGS; Bogart, M; Bunner, SH; Hanania, NA; Ismaila, AS | 1 |
| Darken, P; Marshall, J; Ouwens, M; Sharma, A; Singh, B; Tansey-Dwyer, D | 1 |
| Compton, C; Haeussler, K; Halpin, DMG; Han, MK; Ismaila, AS; Malmenäs, M; Sharma, R; Vogelmeier, CF | 1 |
| Bengtson, LGS; Buysman, EK; Clark, B; Ferguson, GT; Palli, S; Sargent, A; Sethi, S; Shaikh, A | 1 |
| Abbott, CB; Bangalore, M; Bogart, M; DiRocco, K; McMorrow, D; Packnett, ER | 1 |
2 review(s) available for quinuclidines and fluticasone
| Article | Year |
|---|---|
Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2023 |
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2023 |
5 trial(s) available for quinuclidines and fluticasone
| Article | Year |
|---|---|
Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyspnea; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines; Surveys and Questionnaires | 2018 |
Topics: Adult; Aged; Benzyl Alcohols; Chlorobenzenes; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Switzerland | 2018 |
COPD exacerbation costs in the IMPACT study: a within-trial analysis.
Topics: Administration, Inhalation; Adult; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Respiratory Function Tests; Severity of Illness Index | 2020 |
A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
Topics: Administration, Inhalation; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Female; Fluticasone; Forced Expiratory Volume; Glucocorticoids; Humans; Male; Middle Aged; Quinuclidines; Treatment Outcome | 2020 |
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Fluticasone; Humans; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2022 |
7 other study(ies) available for quinuclidines and fluticasone
| Article | Year |
|---|---|
Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cholinergic Antagonists; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Fluticasone; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinuclidines | 2018 |
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Topics: Adrenergic beta-2 Receptor Agonists; Androstadienes; Cost-Benefit Analysis; Delayed-Action Preparations; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Humans; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2018 |
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system.
Topics: Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chile; Chlorobenzenes; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Fluticasone; Forced Expiratory Volume; Humans; Public Health; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Treatment Outcome | 2022 |
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
Topics: Administration, Inhalation; Androstadienes; Bayes Theorem; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delivery of Health Care; Double-Blind Method; Drug Combinations; Fluticasone; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinuclidines | 2022 |
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Topics: Administration, Inhalation; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Patient Acceptance of Health Care; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies | 2023 |
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
Topics: Administration, Inhalation; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Fluticasone; Humans; Patient Acceptance of Health Care; Pneumonia; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Tiotropium Bromide | 2023 |
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Female; Fluticasone; Humans; Male; Medicare; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Retrospective Studies; United States | 2023 |